脉冲生物科学公司 2025年季度报告

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). The number of shares outstanding of the registrant’s common stock as of April 30, 2025:67,273,862 Table of Contents TABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item1. Financial Statements (unaudited): Condensed Consolidated Balance Sheets as of March 31, 2025 and December31, 2024Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three-MonthPeriods EndedMarch 31, 2025 and 2024Condensed Consolidated Statements of Cash Flows for the Three-MonthPeriods Ended March 31, 2025 and 2024 PART II. OTHER INFORMATION Item1. Legal ProceedingsItem 1A. Risk FactorsItem2. Unregistered Sales of Equity Securities and Use of ProceedsItem 3. Default Upon Senior SecuritiesItem4. Mine Safety DisclosuresItem 5. Other InformationItem6. Exhibits “Pulse Biosciences,” the Pulse logos and other trademarks or service marks that we use in connection with the operation ofour business appearing in this quarterlyreport on Form10-Q(this "QuarterlyReport"), including CellFX, CellFX CloudConnect,CellFX Marketplace, Nano-pulse Stimulation, nsPFA, nano-PFA, CellFX nsPFA, and NPS, are the property of Pulse Biosciences,Inc. Solely for your convenience, some of our trademarks and trade names referred to in this QuarterlyReport are listed withoutthe®andTMsymbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks and trade names.Also, this QuarterlyReport may contain additional trade names, trademarks or service marks of others, which are the property of Unless expressly indicated or the context requires otherwise, the terms “Pulse,” “Company,” “we,” “us,” and “our,” in thisdocument refer to Pulse Biosciences, Inc., a Delaware corporation, and, where appropriate, its wholly owned subsidiaries. PULSE BIOSCIENCES, INC.Condensed Consolidated Balance Sheets PULSE BIOSCIENCES, INC.Condensed Consolidated Statements of Operations and Comprehensive Loss PULSE BIOSCIENCES, INC.Condensed Consolidated Statements of Cash Flows PULSE BIOSCIENCES, INC.Notes to Condensed Consolidated Financial Statements 1.Description of the Business Pulse Biosciences, Inc. is a novel ablation company committed to health innovation using itspatented Nano-pulseStimulation (“NPS”) technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy,each less than a millionth of asecondlong, to nonthermally clear or kill targeted cells. NPS technology, also referred to asNanosecond Pulsed-Field Ablation (“nsPFA”) technology when used to ablate cellular tissue, can be used to treat a variety ofmedical conditions for which an optimal solution remains unfulfilled. The Companydeveloped itsproprietary CellFX System, anovel nsPFA delivery platform, and commercialized the initial application of its nsPFA technology to treat benign lesions of theskin. In parallel, the Company hasdesigned a variety of applicators, or disposables, to explore the potential use of the CellFXplatform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose and throat.These applicators include devices for open surgical procedures, endoscopic or minimally invasive procedures, and endoluminal The Company was incorporated in Nevada onMay 19, 2014.OnJune 18, 2018,the Company reincorporated from the Stateof Nevada to the State of Delaware. The Company is located in Miami, Florida, and continues to maintain its offices in Hayward, The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital. TheCompany doesnotcurrently have any material cash flows from operations. Itcurrently generatesnorevenue and will need to raise 2.Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with theCompany’sDecember 31, 2024audited Consolidated Financial Statements and include all adjustments, consisting of only normalrecurring adjustments, necessary to fairly state the information set forth herein. The condensed consolidated financial